Clopidogrel Market - Global Industry Analysis, Size, Share, Trends and Forecast 2017 - 2025
Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are in clinical trials. As a result, the drug did not face much competition and has taken over the global market, with its array of application constantly expanding.
The substantial and high-level evidence gathered over the years support the use of Clopidogrel for reduction of mortality and morbidity patients with acute coronary syndrome, myocardial infarction, and a number of other indications. As a result, the drug has developed a formidable presence in the global market over the years. Moreover, the drug’s relative ease of use, low rate of incidence of adverse reactions, and good tolerability have made it the de-facto antiplatelet agent for the reduction of atherosclerotic events in patients.
These factors have helped the global Clopidogrel market to tread along an excellent growth path in the past few years and the market is expected to embark upon a healthy growth path in the next few years as well. However, the overall profitability of the market has reduced to a certain extent owing to entry of a number of generic products post the patent expiry of Clopidogrel manufacture in 2013. Nevertheless, the vast pool of patients prescribed Clopidogrel on an annual basis across the globe will allow market players excellent growth prospects in the next few years.
Clopidogrel is an antiplatelet agent of thienopyridine, which is primarily used to prevent the blood clots and help against cardiovascular problems associated with the blood clotting. The medications for inhibiting blood clots after a recent heart stroke also use clopidogrel, which is a white colored powder that is insoluble in water at neutral pH but freely soluble at pH1. Clopidogrel was the second most successful drug trailing behind Pfizer’s Lipito in 2010. Sold under the brand name Plavix, and marketed by Sanofi and Bristol-Myers Squibb, the demand for clopidogrel is escalating due to the increasing number of heart attack cases across the globe.
The patent of clopidogrel manufacturing got expires on Market 31, 2012 and is expected to prompt pharmaceutical companies to venture into clopidogrel drug manufacturing. Moreover, companies such as Dr. Reddy’s have acquired the approval to manufacture clopidogrel 300mg. Furthermore, several other organizations such as Roxane Laboratories, Aurobindo Pharma, Sun Pharma, Torrent Pharmaceuticals, and Apotex Crop have gained approval for marketing clopidogrel 75mg. Clopidogrel is also used with aspirin to treat worsening chest pain and to keep blood vessels open and present blood clots after certain heart related operations.
The primary factor for the increased demand for clopidogrel is the mounting population across the world who are suffering from cardiovascular diseases and related problems. Additionally, the changing lifestyle and increase in number of patients related with cardiovascular diseases among the emerging economies in the Asia Pacific region are also expected to be the major consumers for clopidogrel in the next six years. Moreover, the patent expiry of clopidogrel drug is anticipated to open floodgates for various pharmaceutical companies to venture into production of clopidogrel drug.
According to the World Heart Federation, nearly 15 million people suffer from heart attack or related problems globally. Out of these, roughly six million of these patients die while another five million are disabled permanently. This vast patient base is the primary factor that will sustain the demand during the forecast period.
Currently, North America and Europe contribute to the maximum demand for clopidogrel, owing to factors such as robust healthcare infrastructure and high affordability of the residents in this region. However, several countries in the region of Asia Pacific, such as China, India, and Japan are aggressively working towards improving their healthcare sector with the help of favorable policies by the localized governments and increasing disposable income among the urban population. Asia Pacific is home for nearly half of the world’s population, which makes for a high quantity of patient base. Additionally, these regions also have skilled labor at low cost which is encouraging players in the market to invest actively and tap the unmet demand.
Some of the key players in the global clopidogrel market are Pfizer, Dr Reddy’s, Apotex Corp, Roxane Laboratories, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharma.
The study presents a granular assessment and quantitative evaluation of:
The region-wise assessment includes market dynamics in:
The study is prepared with the help of an extensive primary and secondary research. Primary research includes but not limited to interactions, interviews, surveys, and events. Opinions of policy makers and industry experts are carefully integrated into the insights to complement primary research. Volumes of secondary data gleaned through renowned paid sources, annual statements, reputed journals, and government documents offer insights into current dynamics and key evolution trajectories the market is likely to assume. The research employs various industry-wide analytics methods and well-established methodologies to ascertain the attractiveness of key segments. Further, it evaluates the lucrativeness of key regions and factors underlying their maturity. The insights notably include a detailed analysis of forces behind vendor differentiation and offers insight into investment-decision making by prominent players.
The report strives to enlighten businesses and industry stakeholders on multiple facets of the growth dynamic of the market, the key of which include answers to:
Note: Utmost care has invariably been taken to present data and arrive at statistics at all the TMR Research reports. Meanwhile, some recent developments and new industry trends may take time to be included in the reports.
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report